Thyroid Cancer Clinical Trial
— Dysphagia-TTOfficial title:
Pre-and Post-operative Risk Factors Affecting the Incidence and Severity of Dysphagia Following Total Thyroidectomy: An International Multi-centric Prospective Randomized Controlled Clinical Trial (RCT)
The most common and feared complications of total thyroidectomy are vocal cord paralyses and hypocalcemia. However, post-thyroidectomy dysphagia is not uncommon and has important consequences on the quality of life (QoL). It should be taken seriously by all clinicians.
Status | Recruiting |
Enrollment | 500 |
Est. completion date | June 2021 |
Est. primary completion date | June 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 17 Years and older |
Eligibility |
Inclusion Criteria: - Patients with benign or malignant thyroid disorder (multinodular goitre, toxic goitre, thyroid carcinoma) - Patients with total thyroidectomy (TT) indication - Patients over 17 year-old Exclusion Criteria: - Patients without thyroid disease - Patients with thyroid disorder, but prepared for surgery other than TT - Healthy volunteers - Patients below 17 y/o |
Country | Name | City | State |
---|---|---|---|
Turkey | Umraniye Education and Research Hospital, Health Sciences University | Istanbul |
Lead Sponsor | Collaborator |
---|---|
Umraniye Education and Research Hospital |
Turkey,
Exarchos ST, Lachanas VA, Tsiouvaka S, Tsea M, Hajiioannou JK, Skoulakis CE, Bizakis JG. The impact of perioperative dexamethasone on swallowing impairment score after thyroidectomy: a retrospective study of 118 total thyroidectomies. Clin Otolaryngol. 2016 Oct;41(5):615-8. doi: 10.1111/coa.12547. Epub 2016 Feb 8. — View Citation
Hashemian M, Khorasani B, Tarameshlu M, Haghani H, Ghelichi L, Nakhostin Ansari N. Effects of Dysphagia Therapy on Swallowing Dysfunction after Total Thyroidectomy. Iran J Otorhinolaryngol. 2019 Nov;31(107):329-334. doi: 10.22038/ijorl.2019.36233.2193. — View Citation
Rihn JA, Kane J, Albert TJ, Vaccaro AR, Hilibrand AS. What is the incidence and severity of dysphagia after anterior cervical surgery? Clin Orthop Relat Res. 2011 Mar;469(3):658-65. doi: 10.1007/s11999-010-1731-8. — View Citation
Scerrino G, Tudisca C, Bonventre S, Raspanti C, Picone D, Porrello C, Paladino NC, Vernuccio F, Cupido F, Cocorullo G, Lo Re G, Gulotta G. Swallowing disorders after thyroidectomy: What we know and where we are. A systematic review. Int J Surg. 2017 May;4 — View Citation
Shimizu M, Kobayashi T, Jimbo S, Senoo I, Ito H. Clinical evaluation of surgery for osteophyte-associated dysphagia using the functional outcome swallowing scale. PLoS One. 2018 Aug 1;13(8):e0201559. doi: 10.1371/journal.pone.0201559. eCollection 2018. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluation of Dysphagia-Subjective Survey Form | Subjective survey form to be filled- a self-evaluation questionnaire-to evaluate 'Change from baseline postoperative (po) day 1-3 to week 2, po week 6, po week 16, po week 24, po week 36 and po week 48 (last). A new form will be filled in for each outpatient clinic control. assessing common dysphagia symptoms- includes 6 items scored within a range of 0 (without swallowing alterations) to 24 (maximum swallowing dysfunction). |
12 months | |
Primary | Evaluation of Dysphagia-Objective Functional Outcome Swallowing Score (FOSS) | Objective survey form to be filled- a clinician-oriented questionnaire assessing the swallowing function objectively, from stage I (normal function) to stage V (no oral intake). To evaluate change in dysphagia from baseline po day 1-3 to .po week 2, po week 6, po week 16, po week 24, po week 36 and po week 48 (last). A new form will be filled in for each outpatient clinic control. | 12 months | |
Primary | Evaluation of Dysphagia- ENT Consultation | Flexible fiberoptic laryngoscopy (any anatomic explanation for dysphagia? YES or NO? To evaluate change in dysphagia from baseline at postoperative (po) week 6 to po week 24, po week 48 (last). | 12 months | |
Primary | Evaluation of Dysphagia- Neurology Consultation | EMG-electromyography test (any anatomic and/or physiologic dysfunction? YES or NO? To evaluate change in dysphagia from baseline at postoperative (po) week 6 to po week 24, po week 48 (last). | 12 months | |
Primary | Evaluation of Dysphagia- Esophago-gastro-duodenoscopy (EGD) | Any anatomic defect? EGD will be performed once at Postoperative (po) week 6. | 6 weeks | |
Secondary | Evaluation of Standard Dysphagia Rehabilitation | 6-week treatment, starting from po week 6, for all patients with dysphagia- ending at po week 12. Any improvement after 6-week treatment? evaluate at po week 12 and please answer: Any improvent in dysphagia symptom? -YES or NO? | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05774535 -
Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery
|
||
Withdrawn |
NCT04224792 -
Effects of Exercise Training on Fatigue in Thyroid Cancer Survivors
|
N/A | |
Completed |
NCT01728623 -
A Study of E7080 in Subjects With Advanced Thyroid Cancer
|
Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT02911155 -
Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
|
||
Recruiting |
NCT05025046 -
NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules
|
||
Not yet recruiting |
NCT03978351 -
The Role of Midkine in Diagnosis of Thyroid Cancer
|
||
Completed |
NCT02658513 -
Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
|
||
Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 | |
Withdrawn |
NCT01994200 -
Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients
|
Phase 1/Phase 2 | |
Completed |
NCT02375451 -
Effect of Childhood Radioiodine Therapy on Salivary Function
|
N/A | |
Terminated |
NCT01403324 -
Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer
|
N/A | |
Completed |
NCT00970359 -
Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
|
N/A | |
Completed |
NCT00439478 -
Dental Safety Profile of High-Dose Radioiodine Therapy
|
Phase 4 | |
Completed |
NCT00223158 -
Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer
|
N/A | |
Active, not recruiting |
NCT04544111 -
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
|
Phase 2 | |
Completed |
NCT04876287 -
Salivary dysfuncTion After Radioiodine Treatment
|
||
Recruiting |
NCT06073223 -
Intervention to Decrease Overtreatment of Patients With Low-risk Thyroid Cancer
|
N/A | |
Recruiting |
NCT06037174 -
Comparison of Quality of Life in Patients With Differentiated Thyroid Carcinoma Undergoing Different Surgery
|
||
Recruiting |
NCT04952493 -
Anlotinib or Penpulimab in Combination With RAI for DTC
|
Phase 2 |